Compare
Aytu Biopharma, Inc vs Journey Medical Corp vs Agios Pharmaceuticals, Inc. vs Fortress Biotech, Inc.
| Latest fiscal year | Aytu Biopharma, Inc AYTU | Journey Medical Corp DERM | Agios Pharmaceuticals, Inc. AGIO | Fortress Biotech, Inc. FBIO |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $57.57M | $61.24M | $54.03M | $63.26M |
| Revenue growth (YoY) | -13.3% | +11.1% | +48.0% | +9.7% |
| Gross margin | 64.0% | 65.8% (computed) | 88.3% (computed) | 66.9% (computed) |
| Operating margin | -14.4% | -13.3% | -873.9% | -111.0% |
| Net margin | -24.8% | -18.7% | -764.0% | 10.8% |
| Net income | -$14.25M | -$11.43M | -$412.78M | $6.82M |
| EPS (Diluted) | n/a | -$0.47 | -$7.12 | -$0.07 |
| Operating cash flow | $3.28M | -$12.44M | -$372.98M | -$65.78M |
| Free cash flow | $3.25M | n/a | -$377.29M | n/a |
| Cash & equivalents | $26.31M | $24.09M | $89.13M | $79.38M |
| Total assets | $105.01M | $94.59M | $1.30B | $185.55M |
| Total liabilities | n/a | $62.74M | $104.11M | $123.36M |
| Shareholders' equity | $35.27M | $31.85M | $1.19B | $49.87M |
| Return on year-end equity | -40.4% | -35.9% | -34.6% | 13.7% |
| Shares outstanding | 10.73M | n/a | 58.45M | 31.36M |
Revenue, most recent five fiscal years
| Fiscal year | Aytu Biopharma, Inc | Journey Medical Corp | Agios Pharmaceuticals, Inc. | Fortress Biotech, Inc. |
|---|---|---|---|---|
| Latest | $57.57M Ended 2026-06-30 | $61.24M Ended 2025-12-31 | $54.03M Ended 2025-12-31 | $63.26M Ended 2025-12-31 |
| 1 year earlier | $66.38M Ended 2025-06-30 | $55.13M Ended 2024-12-31 | $36.50M Ended 2024-12-31 | $57.67M Ended 2024-12-31 |
| 2 years earlier | $65.18M Ended 2024-06-30 | $59.66M Ended 2023-12-31 | $26.82M Ended 2023-12-31 | $84.51M Ended 2023-12-31 |
| 3 years earlier | $107.40M Ended 2023-06-30 | $71.00M Ended 2022-12-31 | $14.24M Ended 2022-12-31 | $75.74M Ended 2022-12-31 |
| 4 years earlier | $96.67M Ended 2022-06-30 | $63.13M Ended 2021-12-31 | $0 Ended 2021-12-31 | $68.79M Ended 2021-12-31 |